New Market Models for Supply – Risk Mitigation, GPOs & Stability | ATW 2025
How can the advanced therapies industry build a more stable and resilient supply chain? This session explores new market models for supply in cell and gene therapy, focusing on risk mitigation strategies, Group Purchasing Organizations (GPOs), and long-term supply chain stability.
💡 Highlights:
🔥 Fireside chat with George Eastwood & William Beck on supply chain challenges
📜 Phyllis Warkertin discusses FACT accreditation in emerging markets
🩸 Sam Keith shares lessons from the U.S. blood industry on supply stability
🔎 Panel discussion & live Q&A
Speakers:
🔹 George Eastwood – Executive Director, Emily Whitehead Foundation
🔹 William Beck – Director, Supply Chain, BlueRock Therapeutics
🔹 Phyllis Warkertin – Medical Director, Foundation for the Accreditation of Cellular Therapies (FACT)
🔹 Sam Keith – SVP of Supply Chain & Business Development, Blood Centers of America (BCA)
🎟️ Join us for Advanced Therapies Week 2026!
🔹 Pre-register now → https://ow.ly/5Ssp50Vaotw
📖 Download the ATW 2025 Show Brochure → https://ow.ly/raF450Vaouz
#AdvancedTherapies #SupplyChain #CellAndGeneTherapy #GPOs #RiskMitigation #FACTAccreditation #BloodIndustry #ATW25